Curbing Appetite with Oxytocin
Wednesday | October 04, 2017 | Eric Hollander, M.D.
The rare neurodevelopmental genetic disorder Prader-Willi Syndrome (PWS) is characterized by compulsive eating (hyperphagia). The resulting obesity is the leading cause of deaths for people with PWS. Signaling by the hormone oxytocin—which normally acts on brain receptors to inhibit people from eating—is inadequate in PWS, and giving supplemental oxytocin to mouse models of the disorder is known to reduce food intake and body weight. Eric Hollander, M.D., has received a three-year, $1.49 million grant from the U.S. Food and Drug Administration to study whether oxytocin can be safely and effectively given intranasally PWS patients to reduce hyperphagia.
Read the original article here.
Dr. Hollander is a Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine and Director of the Autism and Obsessive Compulsive Spectrum Program, and the Anxiety and Depression Program, at Montefiore Medical Center and the Albert Einstein College of Medicine. Previously he served as the Esther and Joseph Klingenstein Professor and Chair of Psychiatry at the Mount Sinai School of Medicine and was Director of the Seaver and NY Autism Center of Excellence in New York City. Before then he served as Associate Professor of Clinical Psychiatry at the Columbia University College of Physicians and Surgeons in New York.
His areas of research include CBDV in Autism Spectrum Disorder (ASD); Oxytocin in Prader Willi Syndrome (PWS); Vasopressin 1a antagonists in ASD; alpha-1 chemotrypsin in ASD; Intermittent Explosive Disorder; Tourette Syndrome; TMS in OCD and ASD